References
- Bardelmeijer, H.A., Beijnen, J.H., Brouwer, K.R., Rosing, H., Nooijen, W.J., Schellens, J.H., van Tellingen, O. (2000). Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res. 6:4416–21.
- Cavalli, R., Trotta, F. (2009). Characterization and applications of new hyper-cross-linked cyclodextrins. Compos Interface. 16:39–48.
- Cavalli, R., Trotta, F., Tumiatti, W. (2006). Cyclodextrin-based nanosponges for drug delivery. Incl Phenom Macrocycl Chem. 56:209–13.
- Diehl, K.H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., Vidal, J.M., Vorstenbosch, C. (2001). A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 21:15–23.
- Doyle, L.A., Ross, V. (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 22:7340–58.
- Gao, P., Rush, B.D., Pfund, W.P., Huang, T., Bauer, J.M., Morozowich, W., Kuo, M.S., Hageman, M.J. (2003). Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci. 92:2386–98.
- Harris, J.W., Rahman, A., Kim, B.R., Guengerich, F.P., Collins, J.M. (1994). Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54:4026–35.
- Higgins, C.F. (1992). ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 8:67–113.
- Huisman, M.T., Chhatta, A.A., Tellingen, O., Beijnen, J.H., Schinkel, A.H. (2005). MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 116:824–9.
- Kruijtzer, C.M., Beijnen, J.H., Schellens, J.H. (2002). Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist. 7:516–30.
- Malingre, M.M., Beijnen, J.H., Schellens, J.H. (2001). Oral delivery of taxanes. Invest New Drugs. 19:155–62.
- Meerum, J.M., Terwogt, M.M., Malingre, J.H., Beijnen, W.W., Huinink, H., Rosing, F.J., Koopman van, Tellingen, Swart, O.M., Schellens, J.H. (1999). Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 5:3379–84.
- Rahman, A., Korzekwa, K.R., Grogan, J., Gonzalez, F.J., Harris, J.W. (1994). Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P4502C8. Cancer Res. 54:5543–6.
- Rowinsky, E.K. (1993). Clinical pharmacology of Taxol. J Natl Cancer Inst Monogr. 15:25–37.
- Rowinsky, E.K., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G., Donehower, R.C. (1993). Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 20:1–15.
- Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A.H., Smit, J.W., Meijer, D.K., Borst, P., Nooijen, W.J., Beijnen, J.H., van Tellingen, O. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA. 94:2031–5.
- Sutherland, L., Ebner, T., Burchell, B. (1993). The expression of UDP glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol. 45:295–301.
- Swaminathan, S., Pastero, L., Serpe, L., Troota, F., Vavia, P., Aquilano, D., Trotta, M., Zara, G., Cavalli, R. (2009). Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm. 74:193–201.
- Trotta, F., Tumiatti, W. (2003). Cross-linked polymers based on cyclodextrin for removing polluting agents. World patent: WO 03/085002.
- van Asperen, J., Tellingen, O., van der Valk, M.A., Rozenhart, M., Beijnen, J.H. (1998). Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res. 4:2293–7.
- Vavia, P.R., Swaminathan, S., Trotta, F., Torne, S.J. (2007). Formulation of beta cyclodextrin based nanosponges of itraconazole. Incl Phenom Macrocycl Chem. 57:89–94.
- Walle, T., Walle, U.K., Kuma, G.N., Bhalla, K.N. (1995). Taxol metabolism and disposition in cancer patients. Drug Metab Disp. 23:506–12.
- Wang, S., Monagle, J., Mcnulty, C., Putnam, D., Chen, H. (2004). Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J Pharm Sci. 93:2755–67.
- Zuylen, L., Verweij, J., Sparreboom, A. (2001). Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 19:125–41.